reiter outperform increas tp
busi review highlight opportun pharma recent
annual busi review preview note highlight
year meet particular import given challeng
see pharma segment face today encourag
perspect share key market pipelin product well
overal bullish commentari suggest see pharma segment sale
comfort updat model follow
event increas estim notabl stelara tremfya
lai franchis help drive tp upsid possibl
base manag commentari
file blockbust potenti
highlight pipelin opportun plan file ten drug
believ potenti includ previous highlight
asset niraparib prostat cancer bcma car-t
multipl myeloma well newli highlight asset
bispecif egfr/c-met solid tumor crohn
risk also reinforc financi strength possess
addit busi develop focu early-stag asset
jnj area expertis potenti us drug price reform
prepar variou scenario assum neg price go
forward though expect evolut revolut front
valuat risk maintain outperform rate rais
target price target price blend dcf
rel valuat ep estim move
primari risk rate target price
slowdown key pharma growth driver disappoint data
on-going clinic trial signific chang drug price
us surpris verdict on-going talc litig
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
johnson johnson hold compani engag
 manufactur sale rang product health care
field oper compani organ busi
blue sky valuat base greater sale
imbruvica darzalex stelara lai franchis market
product compar current base case assumpt blue sky
valuat base dcf driven wacc
grey sky valuat base lower sale
imbruvica darzalex stelara lai franchis market
product compar current base case assumpt grey sky
valuat base dcf driven wacc
price may rate outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
opportun host group meet member manag
team follow annual busi review gain addit clariti
dynam around certain product well bake expect go
summar compani answer question
busi develop bake revenu number
risk adjust base know today
saw signific gap saw consensu model felt made
sens provid perspect
expect price pressur next year particularli immunolog
mani under-serv area immunolog go price
support
also look oral may opportun
year ago assum price appreci model
assum neg price go forward
assum evolut price reform revolut
leverag come model
scale organ help
portfolio get slant specialti also help
channel mix impact price
price one part access also part
volum growth
rebat reform happen help lower financi burden patient
pay-for pharma provid
possibl see anyth dramat
anyth help access
activ washington put forward propos help patient
thought recent cbo score rebat rule
still tri understand
assum compani lower list price type pass
insurers/pbm also add fee
thought chang protect class
favor keep thing
class patient especi vulner need
think loe period beyond
new product grow
lot question around navig remicad loe
show grow
look almost everyth
area other
larg scale manufactur gt yet possibl
choos smaller organ target first
probabl brain liver next
beyond feel like world readi
capabl actual drive sale rare diseas
hospit cluster rare diseas retin matter
use opportun move technolog proteins/antibodi could reach
ask whether reason
also ask whether scientif expertis leverag
look hurdl rate make sure compens sharehold
alway base scienc
privileg posit make choic
vaccin gram neg bacteria area make push
saw signific need pah opportun drive actelion
time decid leav hcv
chang made organ sinc join
data scienc import area lot work
discoveri develop
newer modal brought given product platform
extraordinari infus talent
think busi develop across segment
multipl part high
premium top make tough
biopharma thing also still cheap
find opportun drive develop commerci
spravato vs pipelin nmda
mechan littl fuzzi
tri copi spravato present dissolv tablet oral etc
see competit around corner next year
pathway connect patient treatment resist could take
mani compani tri fail mechan
encourag may orexin leverag
help get provid set
site qualifi hospit clinic
team help provid understand need get set
sometim provid give drug sometim patient refer
dose come back psychiatrist follow
well site
site would give need good
level dissoci seen product limit
expand portfolio
everi month trial go well
awar teva effort make gener version monthli difficult
still lot room greater penetr
date see non-interchang product see impact
wait data come
differ ozanimod
main differenti lead agent rapidli revers good
select
focus tau seed think factor
drive suggest get efficaci
coupl compani pan tau ahead one
stop amyloid relat program
believ would need start earli impact
ibd invest
part need complet unmet
exampl mucos heal unmet
local gi therapi also opportun
look biomark help classif
expect stelara biosimilar entri
firm date
take continu invest product sign optim around
seek patent deliv meaning innov patient
system
darzalex co-exist bcma
darzalex immunotherapi impact
plan yet work bcma yet
work steroid-fre steroid-minim regimen
one work small compani san diego
everyth clinic autolog cell
heterologu someth talk look
preciou part make sure comfort antigen
futil analysi
ye built look recal detail actual hurdl
charl martineau pm univers toronto figur highlight potenti blockbust drug pipelin expect file
us million
us million
us million except per share valu
good sold
total expens incom
incom tax
ep continu op
dilut ep oper
compani mention price
